AVI BioPharma names chief executive
Chris Garabedian joins US biopharmaceutical firm from Celgene
Garabedian, who has been a director of the Bothell, Washington-based biopharmaceutical firm since June, will continue as a member of the board. David Boyle, who held the post of interim ceo and president, will continue in his role as chief financial officer and senior vice president.
Garabedian brings to AVI broad biotechnology and pharmaceutical experience. He has been vice president of corporate strategy at Celgene since July 2007. Before this, he held several key roles at Gilead Sciences between 1997 and 2005, including vice president of corporate development, vice president of marketing and vice president of medical affairs.
He also held various commercial and product development roles at COR Therapeutics and Abbott Laboratories and began his career as a consultant to the pharmaceutical industry.
‘We believe Chris' experience is ideal for driving products from early development through commercialisation, while also leveraging business development opportunities to unlock further value from our RNA-based therapeutics technology platforms,’ said William Goolsbee, AVI's chairman.
You may also like
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Pharmaceutical
Ardena strengthens executive team to drive its next phase of growth
Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally
Pharmaceutical
Backed by investments exceeding $1 billion, PCI Pharma Services announces major expansion of US sterile fill-finish and drug-device delivery combination capabilities
As pharma manufacturers prioritise US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging
Manufacturing
BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany
The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
Finance
Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings
The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected performance from its oral Wegovy pill